Treatment with a probiotic mixture containing bifidobacterium animalis subsp. Lactis bb12 and enterococcus faecium l3 for the prevention of allergic rhinitis symptoms in children: A randomized controlled trial

Caterina Anania, Vincenza Patrizia Di Marino, Francesca Olivero, Daniela De Canditiis, Giulia Brindisi, Federico Iannilli, Giovanna De Castro, Anna Maria Zicari, Marzia Duse

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Probiotics may prevent the allergic response development due to their antiinflammatory and immunomodulatory effects. The aim of this study is to determine if the prophylactic treatment with a mixture of Bifidobacterium animalis subsp. Lactis BB12 and Enterococcus faecium L3 would reduce symptoms and need for drug use in children with allergic rhinitis (AR). Methods: The study included 250 children aged from 6 to 17 years, affected by AR. Patients were randomly assigned to the intervention group (150) or to the placebo group (100). Patients in the intervention group, in addition to conventional therapy (local corticosteroids and/or oral antihistamines), were treated in the 3 months preceding the onset of symptoms related to the presence of the allergen to which the children were most sensitized, with a daily oral administration of a probiotic mixture containing the Bifidobacterium animalis subsp. Lactis BB12 DSM 15954 and the Enterococcus faecium L3 LMG P-27496 strain. We used Nasal Symptoms Score (NSS) to evaluate AR severity before and after the treatment with probiotics or placebo. Results: the patients in the intervention group had a significant reduction in their NSS after probiotic treatment (p-value = 2.2 × 10−10. Moreover, for the same group of patients, we obtained a significant reduction in the intake of pharmacological therapy. In particular, we obtained a reduction in the use of oral antihistamines (p-value = 2.2 × 10−16), local corticosteroids (p-value = 2.2 × 10−13), and of both drugs (p-value 1.5 × 10−15). Conclusions: When administered as a prophylactic treatment, a mixture of BB12 and L3 statistically decreased signs and symptoms of AR and reduced significantly the need of conventional therapy.

Original languageEnglish
Article number1315
JournalNutrients
Volume13
Issue number4
DOIs
Publication statusPublished - Apr 2021
Externally publishedYes

Keywords

  • Allergic rhinitis
  • Bifidobacterium animalis subsp. Lactis BB12
  • Children
  • Enterococcus faecium L3
  • Probiotics

ASJC Scopus subject areas

  • Food Science
  • Nutrition and Dietetics

Fingerprint

Dive into the research topics of 'Treatment with a probiotic mixture containing bifidobacterium animalis subsp. Lactis bb12 and enterococcus faecium l3 for the prevention of allergic rhinitis symptoms in children: A randomized controlled trial'. Together they form a unique fingerprint.

Cite this